AGTC Genomics

💧 𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐞 𝐂𝐚𝐧𝐜𝐞𝐫 𝐂𝐚𝐫𝐞 𝐰𝐢𝐭𝐡 𝐋𝐢𝐪𝐮𝐢𝐝𝐃𝐱 𝐜𝐭𝐃𝐍𝐀 𝐋𝐢𝐪𝐮𝐢𝐝 𝐁𝐢𝐨𝐩𝐬𝐲 𝐛𝐲 𝐀𝐆𝐓𝐂 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 Say goodbye to invasive procedures! With LiquidDx, you can now monitor and detect cancer through a simple blood draw using circulating tumor DNA (ctDNA). 🌟 𝐖𝐡𝐲 𝐂𝐡𝐨𝐨𝐬𝐞 𝐋𝐢𝐪𝐮𝐢𝐝𝐃𝐱? ✔Non-Invasive: Just a blood draw—no surgery, no hospital admission. ✔Comprehensive: Profiles 523 genes and key genomic markers like TMB, MSI, and HRR. ✔Actionable Insights: Offers guidance on FDA-approved therapies and immunotherapies. ✔Fast Results: Delivered within 7–14 working days from our ISO 15189-certified lab. 🚀 𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 𝐨𝐟 𝐋𝐢𝐪𝐮𝐢𝐝𝐃𝐱 ● Alternative to Tissue Biopsy: Ideal when a tissue sample is inaccessible or unavailable. ● Monitor Therapeutic Response: Track treatment effectiveness and detect residual disease early. ● Identify New Mutations: Stay ahead by detecting tumor heterogeneity and acquired resistance. ● Convenient & Reliable: Suitable for routine monitoring and optimizing personalized treatments. 🧬 𝐇𝐨𝐰 𝐭𝐨 𝐆𝐞𝐭 𝐒𝐭𝐚𝐫𝐭𝐞𝐝 1️⃣ Order the test with your healthcare provider. 2️⃣ Provide a blood sample—no complicated preparation needed. 3️⃣ Receive detailed genomic insights for targeted therapy or clinical trial options. 💡 LiquidDx gives patients and providers a non-invasive, fast, and precise alternative to traditional tissue biopsies, transforming cancer care and enabling precision medicine. 📧 [email protected] 🌐 www.agtcgenomics.com

𝐒𝐞𝐚𝐬𝐨𝐧’𝐬 𝐆𝐫𝐞𝐞𝐭𝐢𝐧𝐠𝐬 𝐟𝐫𝐨𝐦 𝐀𝐆𝐓𝐂 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬! As the year draws to a close, we would like to extend our heartfelt gratitude to our partners, collaborators, and supporters for being an integral part of our journey this year. Your trust, friendship, and unwavering support have been instrumental in making 2024 a successful and fulfilling year for us. Together, we have achieved remarkable milestones in advancing genomics, improving healthcare, and serving our communities better. As we look ahead to 2025, we are excited to continue working alongside you, striving for excellence and innovation in everything we do. Wishing you and your loved ones a joyous Christmas and a New Year filled with health, happiness, and success! Warm regards, The AGTC Genomics Team Caption: Created using Illumina NovaSeq flowcell. Courtesy of creation by Muhammad Nashrulhakim Ahmad Kamal Ariffin

🔬 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦 𝐂𝐚𝐧𝐜𝐞𝐫 𝐂𝐚𝐫𝐞 𝐰𝐢𝐭𝐡 𝐏𝐫𝐞𝐜𝐢𝐬𝐞𝐃𝐱 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐆𝐞𝐧𝐞 𝐏𝐫𝐨𝐟𝐢𝐥𝐢𝐧𝐠 𝐛𝐲 𝐀𝐆𝐓𝐂 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 At AGTC Genomics, we empower precision medicine with PreciseDx, a comprehensive genomic profiling solution designed to maximize the identification of actionable biomarkers and optimize patient outcomes. 🧬 𝐖𝐡𝐲 𝐏𝐫𝐞𝐜𝐢𝐬𝐞𝐃𝐱? ✔Broad Biomarker Analysis: Profile 523 genes including tumor mutational burden (TMB), microsatellite instability (MSI), and homologous recombination repair (HRR) markers. ✔Actionable Insights: Aligns with FDA-approved therapies, clinical trial options, and international guidelines. ✔Applicable for Solid & Blood Cancers: Offers pan-cancer and cancer-specific panels. ✔Fast & Reliable: Results delivered within 7–14 working days from our ISO 15189-certified lab. 🚀 𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 ● Single Test, Multiple Biomarkers: Detects various mutations (SNVs, indels, CNVs, gene fusions) in one test, minimizing the need for rebiopsy. ● Maximizes Sample Efficiency: Avoids sequential testing by consolidating results into a multiplex assay. ● Therapy Matching: Identifies targeted therapies, immunotherapies, and emerging clinical trials based on individual tumor profiles. ● Continuous Reanalysis: Leverage the latest discoveries without retesting or rebiopsy. 🌟 𝐇𝐨𝐰 𝐭𝐨 𝐆𝐞𝐭 𝐒𝐭𝐚𝐫𝐭𝐞𝐝 1️⃣ Order the test via your healthcare provider. 2️⃣ Submit biopsy or blood samples to our lab. 3️⃣ Receive comprehensive insights for personalized treatment planning. 💡 PreciseDx gives you more than just answers—it offers opportunities for better treatment outcomes through precision therapy and cutting-edge clinical trials. For more information: 📧 [email protected] 🌐 www.agtcgenomics.com

𝐀𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲: 𝐀 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐯𝐞 𝐒𝐭𝐞𝐩 𝐅𝐨𝐫𝐰𝐚𝐫𝐝 𝐰𝐢𝐭𝐡 𝐇𝐨𝐬𝐩𝐢𝐭𝐚𝐥 𝐊𝐮𝐚𝐥𝐚 𝐋𝐮𝐦𝐩𝐮𝐫 𝐚𝐧𝐝 𝐏𝐡𝐚𝐫𝐦-𝐃 𝐇𝐞𝐚𝐥𝐭𝐡 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 A big thank you to the Radiotherapy & Oncology Department at Hospital Kuala Lumpur and Pharm-D Health Science for organizing the Continuous Medical Education (CME) program on "Current Advances in Precision Oncology". It was an excellent platform to explore the latest developments in cancer genomics and their clinical utility. The workshop provided valuable insights into the patient journey, particularly how genomics can: ✔Identify hereditary cancer risk ✔Enable cancer early detection ✔Improve cancer diagnosis and treatment recommendations ✔Facilitate cancer monitoring through Minimal Residual Disease (MRD) testing We also had in-depth discussions on the advantages and limitations of various genomic methods, including cost, clinical interpretation, actionability, and utility in real-world clinical settings. Importantly, we acknowledged the challenges in implementing precision medicine and highlighted AGTC Genomics' commitment to collaborating on tailored, purpose-fit solutions. We truly appreciate the input from the doctors and oncologists at HKL for their kind hospitality and thoughtful discussions. These exchanges allow us to design solutions that improve the accessibility and affordability of precision medicine in Malaysia's public healthcare system. Together, we can make precision medicine a reality for all.

Cancer remains a leading cause of death worldwide, with traditional diagnostic and staging methods often failing to detect micrometastatic disease. Advances in circulating tumor DNA (ctDNA) technology enable the detection of molecular residual disease (MRD), improving risk stratification, guiding personalized treatments, and allowing earlier intervention. Tumor-informed and tumor-agnostic ctDNA assays each offer unique advantages. As ctDNA adoption grows, it has the potential to revolutionize cancer management globally, democratizing access to precision oncology and improving patient outcomes.

𝐀𝐆𝐓𝐂 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐓𝐚𝐤𝐞𝐬 𝐀𝐜𝐭𝐢𝐨𝐧 𝐭𝐨 𝐀𝐝𝐝𝐫𝐞𝐬𝐬 𝐑𝐢𝐬𝐢𝐧𝐠 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐂𝐨𝐬𝐭𝐬 𝐢𝐧 𝐌𝐚𝐥𝐚𝐲𝐬𝐢𝐚 𝐰𝐢𝐭𝐡 𝐚 𝐒𝐩𝐨𝐧𝐬𝐨𝐫𝐬𝐡𝐢𝐩 𝐏𝐫𝐨𝐠𝐫𝐚𝐦 𝐟𝐨𝐫 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐂𝐚𝐧𝐜𝐞𝐫 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 At AGTC Genomics, we are on a mission to make precision medicine more accessible and affordable. Through our PRECiSE Cancer Genomics Sponsorship Program, we’re driving change in Malaysian healthcare by reducing costs and improving treatment outcomes for cancer patients. 🧬 𝐇𝐨𝐰 𝐖𝐞 𝐇𝐞𝐥𝐩 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐚𝐧𝐝 𝐃𝐨𝐜𝐭𝐨𝐫𝐬: ✔ Our PreciseDx™ Comprehensive Gene Profiling and LiquidDx™ ctDNA Testing deliver actionable insights by analyzing 523 genes and key genomic signatures like TMB, MSI, and HRR. ✔ Leveraging our proprietary clinical insights algorithm, we provide drug recommendations that help target cancer effectively while avoiding unnecessary side effects. ✔ This ensures the right treatment on the first attempt, significantly reducing treatment costs. 🌍 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐭𝐚𝐧𝐝𝐚𝐫𝐝𝐬, 𝐋𝐨𝐜𝐚𝐥 𝐈𝐦𝐩𝐚𝐜𝐭: The quality of our tests meets global benchmarks, comparable to those in the US, UK, and Singapore, while remaining affordable at just RM 4000 for PreciseDx™ and RM 4500 for LiquidDx™. All tests are conducted locally in our ISO 15189-certified lab, reinforcing quality and reliability. 💙 𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐢𝐧𝐠 𝐭𝐡𝐞 𝐒𝐩𝐨𝐧𝐬𝐨𝐫𝐬𝐡𝐢𝐩 𝐏𝐫𝐨𝐠𝐫𝐚𝐦 This program addresses the current needs of Malaysian patients by providing sponsored access to cutting-edge cancer genomic testing. It’s designed exclusively for Malaysians, reinforcing our commitment to enhancing local healthcare. ✨ 𝐉𝐨𝐢𝐧 𝐔𝐬 𝐢𝐧 𝐁𝐮𝐢𝐥𝐝𝐢𝐧𝐠 𝐕𝐚𝐥𝐮𝐞-𝐁𝐚𝐬𝐞𝐝 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞: Together, let’s bring more value to the Malaysian healthcare system. By advancing precision medicine, we’re not just improving outcomes—we’re creating a future where cancer care is accessible, personalized, and efficient. 📢 𝐓𝐚𝐤𝐞 𝐭𝐡𝐞 𝐅𝐢𝐫𝐬𝐭 𝐒𝐭𝐞𝐩 𝐓𝐨𝐝𝐚𝐲: To learn more about the sponsorship program or sign up, visit www.agtcgenomics.com or contact us at [email protected]. Let’s work together to redefine cancer care for Malaysians. 💪 #PrecisionMedicine #CancerCare #AffordableHealthcare #Genomics #ValueBasedHealthcare #AGTCGenomics

𝐋𝐞𝐯𝐞𝐫𝐚𝐠𝐢𝐧𝐠 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐌𝐞𝐭𝐚𝐠𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐭𝐨 𝐂𝐨𝐦𝐛𝐚𝐭 𝐄𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐀𝐧𝐭𝐢𝐛𝐢𝐨𝐭𝐢𝐜-𝐑𝐞𝐬𝐢𝐬𝐭𝐚𝐧𝐭 𝐏𝐚𝐭𝐡𝐨𝐠𝐞𝐧𝐬 Congratulations Zhen Yun Siew, Chia Ting Khoo, Ghee Khang Ong, Siti Norazlin Binti Muhamad Nor, Pooi Pooi Leong, Wong Siew Tung, Boon Shing Tan , Chee-Onn Leong, Dyoi-E Low and Kenny Voon for their recent publication. Emerging pathogens like Mycobacteroides abscessus often evade detection by conventional methods, posing significant challenges in diagnosis and treatment. Using next-generation sequencing (NGS), this study identified a novel strain of Mycobacteroides abscessus subsp. massiliense, responsible for a chronic skin infection in a human patient, and traced its presence to tree shrews and soil, highlighting potential cross-species and environmental transmission. The pathogen demonstrated resistance to 76.7% of tested antibiotics, with evidence of heteroresistant subpopulations, underscoring the complexity of treating such infections. Epidemiological investigations suggested the pathogen’s transmission via contaminated Java apples, possibly facilitated by tree shrews, emphasizing the role of wildlife and environmental factors in disease spread. These findings showcase the transformative potential of clinical metagenomics for precise pathogen identification and guiding targeted therapies, paving the way for improved infectious disease management and public health strategies.

🎉 𝐀𝐆𝐓𝐂 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐡𝐚𝐬 𝐫𝐞𝐜𝐞𝐢𝐯𝐞𝐝 𝐢𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐜𝐞𝐫𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐠𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐭𝐞𝐬𝐭𝐢𝐧𝐠 🌐✨ AGTC Genomics has received international certification in pharmacogenomics testing! This remarkable achievement is a testament to our unwavering commitment to excellence and innovation in the field of genetic testing. 🧬 𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬: Pharmacogenomics plays a pivotal role in personalized medicine, enabling us to tailor treatments to individuals based on their genetic makeup. With this certification, AGTC Genomics is recognized globally for adhering to the highest standards in accuracy, reliability, and ethical practices in pharmacogenomics testing. 🌍 𝐆𝐥𝐨𝐛𝐚𝐥 𝐑𝐞𝐜𝐨𝐠𝐧𝐢𝐭𝐢𝐨𝐧: This certification is not just a badge of honor; it reflects our dedication to global health advancements. It allows us to collaborate more closely with international healthcare providers, researchers, and patients, bridging gaps and making precision medicine more accessible. 🤝 𝐎𝐮𝐫 𝐂𝐨𝐦𝐦𝐢𝐭𝐦𝐞𝐧𝐭: At AGTC Genomics, we are committed to leveraging this opportunity to enhance our services, expand our global footprint, and continue contributing significantly to the healthcare sector. We are dedicated to providing accurate, efficient, and ethical genetic testing, thus empowering healthcare providers and patients with critical insights into their health and treatment options. 💡 𝐋𝐨𝐨𝐤𝐢𝐧𝐠 𝐀𝐡𝐞𝐚𝐝: This milestone is just the beginning. We are excited about the future, as we continue to innovate and lead in the realm of genomics and personalized medicine. Stay tuned for more updates and developments from our team! We thank our incredible team, partners, and clients for their support and trust in AGTC Genomics. Here's to many more milestones and breakthroughs together!

🔍 𝐃𝐞𝐭𝐞𝐜𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 𝐄𝐚𝐫𝐥𝐲 𝐰𝐢𝐭𝐡 𝐂𝐚𝐧𝐜𝐞𝐫𝐒𝐜𝐫𝐞𝐞𝐧𝐃𝐱 𝐛𝐲 𝐀𝐆𝐓𝐂 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 CancerScreenDx is revolutionizing early cancer detection! A single blood test can now identify over 110 types of cancer, giving you a proactive edge to fight cancer when it's most treatable. 🌟 𝐖𝐡𝐲 𝐂𝐚𝐧𝐜𝐞𝐫𝐒𝐜𝐫𝐞𝐞𝐧𝐃𝐱? ✔Comprehensive Detection: Screen for 110+ types of cancer, surpassing traditional methods. ✔Accurate & Predictive: Pinpoints cancer origin with precision for early intervention. ✔Non-Invasive: One simple blood draw for easy and accessible screening. Fast Turnaround: Results within 7–14 days from our ISO 15189-certified lab. 🧬 𝐇𝐨𝐰 𝐈𝐭 𝐖𝐨𝐫𝐤𝐬 CancerScreenDx detects circulating tumor DNA (ctDNA) in the blood, identifying cancer signals early and accurately predicting their source. This empowers patients and healthcare providers to take timely action with confidence. 🎯 𝐖𝐡𝐨 𝐒𝐡𝐨𝐮𝐥𝐝 𝐆𝐞𝐭 𝐓𝐞𝐬𝐭𝐞𝐝? ● Individuals aged 40+ for routine screening. ● Those with family history of cancer. ● People with previous cancer diagnoses seeking proactive monitoring. ● Anyone with symptoms such as unexplained weight loss, fatigue, or persistent pain. 🚀 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 𝐨𝐟 𝐄𝐚𝐫𝐥𝐲 𝐃𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 ● Higher survival rates with timely treatment. ● Improved quality of life through reduced treatment burdens. ● Cost savings by avoiding advanced-stage treatments. 𝐎𝐫𝐝𝐞𝐫 𝐓𝐨𝐝𝐚𝐲 𝐚𝐧𝐝 𝐓𝐚𝐤𝐞 𝐂𝐨𝐧𝐭𝐫𝐨𝐥 𝐨𝐟 𝐘𝐨𝐮𝐫 𝐇𝐞𝐚𝐥𝐭𝐡! 1️⃣ Order the test through your healthcare provider. 2️⃣ Blood draw at your lab or clinic. 3️⃣ Receive your results in just 7-14 working days. For more information: 📧 [email protected] 🌐 www.agtcgenomics.com

𝐒𝐭𝐫𝐞𝐚𝐦𝐥𝐢𝐧𝐢𝐧𝐠 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐆𝐞𝐧𝐨𝐦𝐢𝐜 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐰𝐢𝐭𝐡 𝐎𝐧𝐥𝐢𝐧𝐞 𝐎𝐫𝐝𝐞𝐫𝐢𝐧𝐠 Efficient workflows are the backbone of effective patient care, especially in oncology practices. Yet, the process of ordering genomic tests can sometimes be time-consuming, disrupting the seamless flow of clinical operations. At AGTC Genomics, we understand these challenges. That’s why we’ve launched our online ordering platform, designed to integrate seamlessly into your practice. We are committed to helping patients access our testing services. Learn more about how our online ordering platform can revolutionize your genomic testing workflow. Visit https://lnkd.in/g99GWzMp to get started today! Together, let’s enhance the speed and precision of cancer care for every patient.